We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NNI:NYSENelnet, Inc. Analysis

Data as of 2026-06-06 - not real-time

$129.03

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Nelnet, Inc. (NNI) is trading at $129.03, just below its 20‑day SMA of 127.47 and well under the 50‑day SMA of 132.71, with the price hovering between the computed support of $116.62 and resistance of $132.22. The RSI of 45.7 and a bullish MACD histogram (+0.26) suggest a neutral‑to‑slightly positive short‑term momentum, while volume trends are decreasing, adding a note of caution. Valuation metrics are attractive: the trailing P/E of 11.22 is markedly below the industry average of 17.0, and the price‑to‑book of 1.24 indicates the stock is trading close to its book value. Dividend sustainability looks solid, with a 1% yield supported by a modest 10.8% payout ratio and strong cash flow generation.
Fundamentally, the company posted a 7.1% year‑over‑year revenue decline to $1.65 billion, yet maintains impressive gross (86.6%) and operating (21.4%) margins. Earnings per share missed consensus, with non‑GAAP EPS of $1.94 falling 27% short of expectations, highlighting near‑term earnings pressure. The balance sheet is heavily leveraged, reflected by a debt‑to‑equity of over 213, but the low beta (≈0.46) and a 30‑day volatility of 44.5% suggest market risk is moderated. Overall, NNI appears undervalued with a reliable dividend, but faces earnings and leverage headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Neutral technical stance with price near support and resistance
  • Recent earnings miss and decreasing volume
  • Attractive valuation but high leverage

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Undervalued metrics versus industry peers
  • Strong dividend yield and low payout ratio
  • Persistent revenue decline and elevated debt levels

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Low P/E and P/B relative to sector suggest upside potential
  • Sustainable dividend provides income cushion
  • Stable cash flow generation despite leverage

Key Metrics & Analysis

Financial Health

Revenue Growth-7.10%
Profit Margin25.34%
P/E Ratio11.2
ROE10.70%
ROA2.63%
Debt/Equity213.54
P/B Ratio1.2
Op. Cash Flow$404.9M
Industry P/E17.0

Technical Analysis

TrendNeutral
RSI45.7
Support$116.62
Resistance$132.22
MA 20$127.47
MA 50$132.71
MA 200$130.92
MACDBullish
VolumeDecreasing
Fear & Greed Index83.02

Valuation

Target Price$135.00
Upside/Downside4.63%
GradeUndervalued
TypeValue
Dividend Yield1.00%

Risk Assessment

Beta0.46
Volatility44.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.